These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19021201)

  • 1. Impact of ASC-H terminology on the detection of HSILs in medically underserved California women.
    Howell LP; Gurusinghe S; Tabnak F
    Diagn Cytopathol; 2009 Feb; 37(2):103-10. PubMed ID: 19021201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing.
    Howell LP; Gurusinghe S; Tabnak F; Sciortino S
    Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria.
    Thrall MJ; Pambuccian SE; Stelow EB; McKeon DM; Miller L; Savik K; Gulbahce HE
    Cancer; 2008 Jun; 114(3):171-9. PubMed ID: 18454461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Pap Test terminology and age in the detection of carcinoma invasive and carcinoma in situ in medically underserved California women.
    Howell LP; Tabnak F; Tudury AJ; Stoodt G
    Diagn Cytopathol; 2004 Apr; 30(4):227-34. PubMed ID: 15048955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for cervical disease in mature women: strategies for improvement.
    Colgan TJ; Clarke A; Hakh N; Seidenfeld A
    Cancer; 2002 Aug; 96(4):195-203. PubMed ID: 12209660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
    Zhao C; Austin RM
    Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytologic-histologic correlation of screening and diagnostic Papanicolaou tests.
    Chute DJ; Covell J; Pambuccian SE; Stelow EB
    Diagn Cytopathol; 2006 Jul; 34(7):503-6. PubMed ID: 16783779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of precursors of cervical cancer with cervical cytology and visual inspection of cervix with acetic Acid.
    Dhaubhadel P; Vaidya A; Choudhary P
    JNMA J Nepal Med Assoc; 2008; 47(170):71-6. PubMed ID: 18709035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comment on diagnosis of atypical squamous cells using new the Bethesda system 2001].
    Wang Y; Bian ML; Liu J
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jan; 39(1):27-9. PubMed ID: 14989984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
    Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of subclassifying high-grade squamous intraepithelial lesions into moderate dysplasia/CIN II versus severe dysplasia/CIN III/CIS in the Bethesda System terminology.
    Howell LP; Zhou H; Wu W; Davis R
    Diagn Cytopathol; 2004 May; 30(5):362-6. PubMed ID: 15108239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.
    Cooper CP; Saraiya M; McLean TA; Hannan J; Liesmann JM; Rose SW; Lawson HW
    J Womens Health (Larchmt); 2005 Oct; 14(8):670-8. PubMed ID: 16232098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of a community outreach intervention to improve follow-up among underserved women at highest risk for cervical cancer.
    Engelstad LP; Stewart S; Otero-Sabogal R; Leung MS; Davis PI; Pasick RJ
    Prev Med; 2005; 41(3-4):741-8. PubMed ID: 16125761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
    Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
    Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic verification of Group III and III D cytological tests with special reference to follow-up].
    Schlegel H; Kühndel K
    Zentralbl Gynakol; 1983; 105(24):1585-96. PubMed ID: 6666444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up.
    Massad LS; Seaberg EC; Wright RL; Darragh T; Lee YC; Colie C; Burk R; Strickler HD; Watts DH
    Obstet Gynecol; 2008 Jun; 111(6):1388-93. PubMed ID: 18515523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?
    Cooper AL; Dornfeld-Finke JM; Banks HW; Davey DD; Modesitt SC
    Obstet Gynecol; 2006 Jan; 107(1):71-6. PubMed ID: 16394042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicability of the Bethesda System 2001 to a public health setting.
    Prandi S; Beccati D; De Aloysio G; Fulgenzi P; Gabrielli M; Ghirardini C; Rivasi F; Saragoni L; de Bianchi PS; Bucchi L
    Cancer; 2006 Oct; 108(5):271-6. PubMed ID: 16948127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cervical cancer screening program at a rural community of South Africa.
    Hoque M; Hoque E; Kader SB
    East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.